Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factorial phase 3 study of pemetrexed versus gemcitabine with or without cisplatin in elderly patients with non-squamous advanced NSCLC
2012-000164-25Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pemetrexed, gemcitabine and cisplatin in Non-small cell lung cancer (NS-NSCLC) (4 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: overall survival. Started Mar 2012; status: completed.
02
Drugs
pemetrexedgemcitabinecisplatin
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2012-000164-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000164-25.